Comparing a BTK inhibitor alone with BTK inhibitor plus venetoclax in leukemia
Compares a BTK inhibitor pill alone with that pill plus venetoclax in CLL.
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Durham, Kansas City, San Francisco, and Seattle, United StatesSee the 4 sites
- Trial code
- Registry title
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Venetoclax
- Ibrutinib, Acalabrutinib, Zanubrutinib
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have taken a BTK inhibitor pill for at least six months and still have detectable disease.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- CLL or SLL that can still be detected in the blood or on imaging. Low risk of tumor lysis syndrome: all lymph nodes under 5 cm (2 in) and lymphocyte count under 25 x 109/L. ECOG performance status 0-2.
- Earlier treatment
- Must be taking a BTK inhibitor (ibrutinib, acalabrutinib or zanubrutinib) for at least six months, at a stable dose for at least the past three months. Must not have had the BTKi plus venetoclax combination before.
Main reasons for not taking part
- CLL or SLL that got worse while on BTK inhibitor treatment
- History of Richter's transformation or prolymphocytic leukemia
- Taking heparin or warfarin as a blood thinner
- Needing more than 20 mg prednisone (or equivalent) a day
- Active infection needing antibiotics through a vein
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) diagnosis
- Patients must have been diagnosed with CLL (> 5000 B-cells per microliter of peripheral blood at any point during the course of their disease) or small lymphocytic lymphoma (SLL) with <5000 B-cells per microliter of blood but with disease-associated lymphadenopathy by 2018 IWCLL criteria
- Prior treatment
- Patients must be currently receiving CLL/SLL directed therapy with a BTKi (i.e., ibrutinib, acalabrutinib, zanubrutinib) for at least six months
- The dose of Bruton Tyrosine Kinase Inhibitor (BTKi) must be stable for at least the past three months
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Detectable or measurable CLL/SLL in blood or imaging during the screening period. Detectable CLL/SLL in the blood is defined either by elevation in absolute lymphocyte count or by diagnostic flow cytometry from blood demonstrating presence of CLL cells
- Low Tumor Lysis Syndrome (TLS) risk, defined as having all lymph nodes less than 5 centimeters (cm) in diameter (radiographically) and absolute lymphocyte count less than 25 x 109/liter (L) in blood, within 30 days of enrollment
- Required initial laboratory values
- Absolute Neutrophil Count (ANC) 1,000/ cubic millimeters (mm3) except if due to bone marrow involvement
- Platelet Count (untransfused) 30,000/cubic millimeters (mm3) except if due to bone marrow involvement
- Calc. Creatinine Clearance 40 milliliters per minute (mL/min) (by Cockcroft-Gault)
- Bilirubin 1.5 x upper limit of normal (ULN) except if due to liver involvement, hemolysis, or Gilbert's disease
- Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) 2.5 x upper limit of normal (ULN) except if due to liver involvement
- Other
- Patients must be able to swallow oral medications and not have the following conditions: disease significantly affecting gastrointestinal absorption, resection of the stomach or small bowel, partial or complete bowel obstruction
- Patients must be able to receive either a xanthine oxidase inhibitor or rasburicase
Who cannot take part
- Prior treatment
- Patients must not have progression of CLL/SLL on Bruton Tyrosine Kinase Inhibitor (BTKi) therapy prior to initiation of the study therapy
- Patients must not have received the combination of Bruton Tyrosine Kinase Inhibitor (BTKi)+ venetoclax previously
- Please note: Intravenous immunoglobulin (IVIG) can cause a false positive hepatitis B serology. If patients receiving routine IVIG have core antibody or surface antigen positivity without evidence of active viremia (negative hepatitis B DNA) they may still participate in the study, must have hepatitis serologies and hepatitis B DNA monitored periodically by the treating physician
- If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load
- Concomitant medications
- Patients must not be receiving active systemic anticoagulation with heparin or warfarin. Patients on warfarin must discontinue the drug for at least 10 days prior to registration on the study
- Chronic concomitant treatment with strong inhibitors of CYP3A4/5 is not recommended on this study. Patients on strong CYP3A inhibitors must discontinue the drug for 14 days prior to registration on the study or discuss with the study principal investigator
- Chronic concomitant treatment with strong CYP3A4/5 inducers is not recommended. Patients must discontinue the drug 14 days prior to registration on the study or discuss with the study principal investigator
- Patients must not require more than 20 milligrams (mg) prednisone or equivalent corticosteroid daily
- Comorbid conditions or other active diseases
- Patients must not have any history of Richter's transformation or prolymphocytic leukemia
- If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable and be on suppressive therapy, if indicated
- Patients with Class III or Class IV heart failure by New York Heart Association, those with unstable angina, and those with uncontrolled arrhythmia are not eligible
- Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy are eligible for this trial
- Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Durham VA Medical Center, Durham, NCDurham, United StatesContact: Daphne Friedman, MDTaking people
- Kansas City VA Medical Center, Kansas City, MOKansas City, United StatesContact: Murali K Nittala, MBBS MS MDTaking people
- San Francisco VA Medical Center, San Francisco, CASan Francisco, United StatesContact: Gerald Hsu, MDTaking people
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Jeannine BartonTaking people
About the trial
What the trial wants to find out
People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax.
Read full original descriptionShow less
The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.
The 2 groups in the trial
- Arm A : Continue BTKi single agentExisting treatment, for comparison
Continue BTKi single agent (monotherapy) Standard Intervention
Treatment: Ibrutinib, Acalabrutinib, Zanubrutinib
- Arm B : BTKi + Venetoclax for 12 cycles, then discontinueTreatment being tested
BTKi + Venetoclax for 12 cycles, then discontinue Experimental Intervention
Treatment: Venetoclax and Ibrutinib, Acalabrutinib, Zanubrutinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Plain-language title
- Comparing a BTK inhibitor alone with BTK inhibitor plus venetoclax in leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06520098, who can take part
- Record updated
- 30 October 2026